JMP Securities initiated coverage of Cross Country with a rating of Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2024 | Outperform → Mkt Perform | Barrington Research | |
| 12/6/2023 | Mkt Perform | JMP Securities | |
| 11/3/2023 | $32.00 → $21.00 | Buy → Hold | Jefferies |
| 6/26/2023 | Outperform | William Blair | |
| 3/10/2023 | $30.00 | Buy | Loop Capital |
| 10/5/2022 | $36.00 | Buy → Hold | Truist |
| 2/24/2022 | $33.00 → $42.00 | Buy | Benchmark |
| 1/27/2022 | $18.00 → $27.00 | Hold → Buy | Jefferies |
Cross Country Healthcare, Inc. (the Company) (NASDAQ:CCRN) today announced financial results for its first quarter ended March 31, 2025. SELECTED FINANCIAL INFORMATION: Variance Variance Q1 2025 vs Q1 2025 vs Dollars are in thousands, except per share amounts Q1 2025 Q1 2024 Q4 2024 Revenue $ 293,408 (23 ) % (5 ) % Gross profit margin* 20.0 % (40 ) bps — bps Net loss attributable to common stockholders $ (490 ) (118 ) % 87 % Diluted EPS $ (0.02 ) $ (0.10 )
Cross Country Healthcare, Inc. ("Cross Country" or the "Company") (NASDAQ:CCRN) today announced that the Company has obtained all requisite stockholder approvals in connection with its proposed acquisition by Aya Healthcare. As previously disclosed, Cross Country and Aya Healthcare expect to complete the transaction in the second half of 2025, subject to the satisfaction or waiver of customary closing conditions specified in the Merger Agreement. Upon completion of the transaction, Cross Country will become a private company and its common stock will no longer trade on the NASDAQ. Cross Country will file the final, certified voting results on a Form 8-K with the U.S. Securities and Exch
Cross Country stockholders to receive $18.61 per share Expands Aya's client service and delivery capabilities with Cross Country's nearly 40-year history of clinical excellence and quality patient care Provides clinicians with greater flexibility and convenience by tapping into the combined pool of nationwide opportunities, with competitive compensation and a world-class experience Creates immediate stockholder value for Cross Country, through a nearly 67 percent premium Aya Healthcare and Cross Country Healthcare today announced that they have entered into a definitive agreement whereby Aya will acquire Cross Country for $18.61 per share in cash in a transaction valued at appr
SCHEDULE 13G - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)
SCHEDULE 13G - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)
10-Q - CROSS COUNTRY HEALTHCARE INC (0001141103) (Filer)
Barrington Research downgraded Cross Country from Outperform to Mkt Perform
JMP Securities initiated coverage of Cross Country with a rating of Mkt Perform
Jefferies downgraded Cross Country from Buy to Hold and set a new price target of $21.00 from $32.00 previously
4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)